Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC).
Pronicka
E
E
Department of Metabolic Diseases, Children's Memorial Health Institute, Warsaw, Poland.
Rowinska
E
E
Bentkowski
Z
Z
Zawadzki
J
J
Holme
E
E
Lindstedt
S
S
D015111:4-Hydroxyphenylpyruvate Dioxygenase / Q000037:antagonists & inhibitors*; D000592:Amino Acid Metabolism, Inborn Errors / Q000150:complications / Q000188:drug therapy*; D002648:Child; D003512:Cyclohexanones / Q000008:administration & dosage / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology*; D008297:Male; D009579:Nitrobenzoates / Q000008:administration & dosage / Q000627:therapeutic use*; D010024:Osteoporosis / Q000188:drug therapy / Q000209:etiology; D010710:Phosphates / Q000097:blood / Q000652:urine; D012016:Reference Values; D014443:Tyrosine / Q000097:blood*; D014527:Uric Acid / Q000097:blood / Q000652:urine
D003512:Cyclohexanones; D004791:Enzyme Inhibitors; D009579:Nitrobenzoates; D010710:Phosphates; D014527:Uric Acid; D014443:Tyrosine; D015111:4-Hydroxyphenylpyruvate Dioxygenase; C077073:nitisinone